Skip to main content
SpringerLink
Log in

The I Allele of the Angiotensin-Converting Enzyme Gene Polymorphism may Determine an Increase in Homocysteine Levels in Fibrate-Treated Subjects

  • Short Communication
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

The aim of the study was to investigate the influence of the angiotensin-converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism on nonlipid effects of statins and fibrates in hypercholesterolemic subjects. C-reactive protein, homocysteine, adhesion molecules, CD40 ligand, interleukin-6 and monocyte chemoattractant protein-1 were measured prior to and following 30 days of simvastatin or fenofibrate therapy. Decreases in all the variables except for adhesion molecules and homocysteine were observed in both treatment groups, without genotype-related differences. Interestingly, fenofibrate treatment led to a significant increase in homocysteine levels (p = 0.03) only in carriers of the I allele. In conclusion, ACE genotype might help identify patients prone to this effect of fibrates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chapman MJ. Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention. Cardiovasc Drugs Ther 2005;19:135–9.

    Article  PubMed  CAS  Google Scholar 

  2. Cignarella A, Bolego C, Paoletti R. Impact of statins on novel risk markers. Cardiovasc Drugs Ther 2003;17:361–6.

    Article  PubMed  CAS  Google Scholar 

  3. Ushiroyama T, Ikeda A, Higashio S, Ueki M. Coagulofibrinolytic assessment of effects of bezafibrate on hypertriglyceridemia in postmenopausal women. Blood Coagul Fibrinolysis 2000;11:709–14.

    Article  PubMed  CAS  Google Scholar 

  4. Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 2001;77:247–53.

    Article  PubMed  CAS  Google Scholar 

  5. Šebaštjen M, Keber I, Žegura B, et al. Statin and fibrate treatment of combined hyperlipidaemia: the effects on some novel risk factors. Thromb Haemost 2004;92:1129–35.

    Google Scholar 

  6. Milionis HJ, Papakostas J, Kakafika A, Chasiotis G, Seferiadis K, Elisaf MS. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. J Clin Pharmacol 2003;43:825–30.

    Article  PubMed  CAS  Google Scholar 

  7. Dierkes J, Westphal S, Kunstmann S, Banditt P, Lössner A, Luley C. Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate. Atherosclerosis 2001;158:161–4.

    Article  PubMed  CAS  Google Scholar 

  8. Rolland PH, Friggi A, Barlatier A, et al. Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril–hydrochlorothiazide combination prevents elastic alterations. Circulation 1995;91:1161–74.

    PubMed  CAS  Google Scholar 

  9. Fu YF, Xiong Y, Fu SH. Captopril restores endothelium-dependent relaxation of rat aortic rings after exposure to homocysteine. J Cardiovasc Pharmacol 2003;42:566–72.

    Article  PubMed  CAS  Google Scholar 

  10. Marian AJ, Safavi F, Ferlic L, Dunn JK, Gotto AM, Ballantyne CM. Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response to plasma lipids and coronary atherosclerosis to treatment with fluvastatin. J Am Coll Cardiol 2000;35:89–95.

    Article  PubMed  CAS  Google Scholar 

  11. Maitland-van der Zee AH, Stricker BHCh, Klungel OH, et al. Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism. Atherosclerosis 2004;175:377–9.

    Article  PubMed  CAS  Google Scholar 

  12. Potaczek DP, Undas A, Iwaniec T, Szczeklik A. The angiotensin-converting enzyme gene insertion/deletion polymorphism and effects of quinapril and atorvastatin on haemostatic parameters in patients with coronary artery disease. Thromb Haemost 2005;94:224–5.

    PubMed  CAS  Google Scholar 

  13. Bossé Y, Vohl MC, Dumont M, et al. Influence of the angiotensin-converting enzyme gene insertion/deletion polymorphism on lipoprotein/lipid response to gemfibrozil. Clin Genet 2002;62:45–52.

    Article  PubMed  Google Scholar 

  14. Mansoor MA, Svardal AM, Ueland PM. Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine, and glutathione in human plasma. Anal Biochem 1992;200:218–29.

    Article  PubMed  CAS  Google Scholar 

  15. Graham IM, O'Callaghan P. Vitamins, homocysteine and cardiovascular risk. Cardiovasc Drugs Ther 2002;16:383–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Jagellonian University School of Medicine, 8 Skawinska Str., 31-066, Cracow, Poland

    Daniel P. Potaczek, Magdalena Celinska-Lowenhoff & Andrew Szczeklik

  2. Institute of Cardiology, Jagellonian University School of Medicine, Cracow, Poland

    Anetta Undas

Authors
  1. Daniel P. Potaczek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anetta Undas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Magdalena Celinska-Lowenhoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrew Szczeklik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew Szczeklik.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Potaczek, D.P., Undas, A., Celinska-Lowenhoff, M. et al. The I Allele of the Angiotensin-Converting Enzyme Gene Polymorphism may Determine an Increase in Homocysteine Levels in Fibrate-Treated Subjects. Cardiovasc Drugs Ther 20, 229–232 (2006). https://doi.org/10.1007/s10557-006-8374-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-006-8374-8

Key words

Search

Navigation